BIO-TECHNE TO SEEK APPROVAL TO IMPLEMENT FOUR-FOR-ONE STOCK SPLIT

About this update from Bio-techne Corp

[{"type":"text","content":"MINNEAPOLIS, Sept. 1, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its plan to request shareholder approval during its upcoming 2022 Annual Meeting of Shareholders (the \"Annual Meeting\") for an increase in the total number of authorized shares of common stock through an amendment to the Company's Articles of Incorporation to implement a four-for-one forward stock split in the form of a stock dividend. The proposed amendment to the Company's Articles of Incorporation will be voted on by shareholders during Bio-Techne's Annual Meeting on October 27, 2022. Following shareholder approval, Bio-Techne's Board of Directors intends to declare the stock split and set a record date and distribution date for the stock dividend. The stock dividend is expected to occur in the Company's second quarter of fiscal 2023.\nAdditional details regarding Bio-Techne's Annual Meeting, as well as the proposed four-for-one stock split can be found in the preliminary proxy that was filed with the Securities and Exchange Commission (SEC) on September 1, 2022, and the definitive proxy statement which is expected to be filed with the SEC on or about September 16, 2022.\nForward Looking Statements:Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding the proposed stock split. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues resulting from the COVID-19 pandemic, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.\nFor ad...

More updates from Bio-techne Corp